Compare SNEX & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNEX | PCVX |
|---|---|---|
| Founded | 1924 | 2013 |
| Country | United States | United States |
| Employees | 5400 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.0B |
| IPO Year | 1996 | 2020 |
| Metric | SNEX | PCVX |
|---|---|---|
| Price | $65.97 | $65.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $108.67 |
| AVG Volume (30 Days) | 754.2K | ★ 1.8M |
| Earning Date | 11-23-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $132,378,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.29 | ★ N/A |
| Revenue Growth | ★ 32.53 | N/A |
| 52 Week Low | $63.25 | $39.87 |
| 52 Week High | $141.99 | $90.75 |
| Indicator | SNEX | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 58.82 |
| Support Level | $64.53 | $52.91 |
| Resistance Level | $71.09 | N/A |
| Average True Range (ATR) | 2.53 | 4.04 |
| MACD | 0.22 | 0.98 |
| Stochastic Oscillator | 36.70 | 30.10 |
StoneX Group Inc is a brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.